Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Tappero, S; Cano, Garcia, C; Incesu, RB; Piccinelli, ML; Barletta, F; Morra, S; Scheipner, L; Tian, Z; Saad, F; Shariat, SF; Borghesi, M; Terrone, C; Karakiewicz, PI.
Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy.
Surg Oncol. 2023; 48:101947 Doi: 10.1016/j.suronc.2023.101947
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Scheipner Lukas
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: PURPOSE: To test the effect of conditional survival on 36-months' cancer-specific mortality (CSM)-free survival in non-metastatic muscle-invasive adenocarcinoma of the bladder (ACB). MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2000-2018), ACB patients treated with radical cystectomy (RC) were identified. Multivariable competing risks regression (CRR) analyses assessed the independent predictor status of organ-confined (OC, T₂N₀M₀) vs non-organ-confined stage (NOC, T_3-4N₀M₀ or T_anyN_1-3M₀) on CSM. Conditional 36-months' CSM-free survival estimates were computed based on event-free intervals of 12, 24, 36, 48 and 60 months after RC, according to stage. RESULTS: Of 475 ACB patients, 132 (28%) harbored OC vs 343 (72%) harbored NOC stage. In multivariable CRR models, NOC vs OC stage independently predicted lower CSM (hazard ratio 3.55; 95% CI 2.66, 5.83; p < 0.001). Conversely, neither chemotherapy nor radiotherapy were independently associated with CSM. In OC stage, 36-months' CSM-free survival rate was 84% at baseline. Provided event-free intervals of 12, 24, 36, 48 and 60 months, conditional 36-months' CSM-free survival estimates were 84, 87, 87, 89 and 89%. In NOC stage, 36-months' CSM-free survival rate was 47% at baseline. Provided event-free intervals of 12, 24, 36, 48 and 60 months, conditional 36-months' CSM-free survival estimates were 51, 62, 69, 78 and 85%. CONCLUSIONS: Conditional survival estimates provide better insight into survival of patients with longer event-free follow-up. In consequence, conditional survival estimates might be highly valuable for individual patient counselling.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Urinary Bladder - surgery; Cystectomy - administration & dosage; Carcinoma, Transitional Cell - surgery; Urinary Bladder Neoplasms - pathology; Muscles - administration & dosage
Find related publications in this database (Keywords): Adenocarcinoma; Bladder cancer; Conditional survival; Radical cystectomy; SEER